| Literature DB >> 33042359 |
Ludger Klimek1, Tilman Huppertz2, Ali Alali1, Magdalena Spielhaupter3, Karl Hörmann4, Christoph Matthias2, Jan Hagemann2.
Abstract
Filtering facepiece particle (FFP) masks are important items of personal protective equipment in fighting COVID-19 pandemic. They shall protect the wearer of the mask from particles, droplets, and aerosols, but they also can prevent the spread of aerosol-transmitted viruses if the wearer becomes infected. Most often, FFP respirators consist of multiple layers of non-woven fabric made from polypropylene. Worldwide, FFP respirators are subject to various regulatory standards that specify physical properties and performance characteristics. During the SARS-CoV-2 pandemic, health authorities have temporarily repealed standards for respirators. We report on 46 patients that presented with rhinitis-like symptoms strongly associated to the use of FFP masks. Some of them were obliged to use FFP masks in their work environment. Nasal endoscopy showed edemata of the nasal mucosa that significantly decreased after a period of non-use of FFP masks. Subjectively reported symptom levels decreased after cessation of FFP use for 3 or more days. The presence of polypropylene fibres isolated from nasal rinsing solution was significantly associated with the use of FFP masks in our patients. Material safety and performance deregulation of FFP masks can pose a health risk. Thus, especially health care professionals and other individuals with occupational need for FFP masks should be aware of possible hazards that come with COVID-19 pandemic protection measures.Entities:
Keywords: Allergy; CE, conformité européenne label indicating conformity to the EU-regulation 765/2008; COVID-19, coronavirus disease from the year 2019; ECP, eosinophilic cationic protein; FFP, filtering facepiece particle; FFP2-Mask; Filtering facepiece masks; Irritant rhinitis; KN95-Mask; N95 / KN95, technical / physical standard for filtering face masks (not penetrated by particles larger 0.3 μm, N/KN indicating that aqueous, but not oily aerosols are filtered; N95-mask; PPE, personal protective equipment; SD / SEM, standard deviation / standard error of the mean; VAS, visual analogue scale; WHO, World Health Organization
Year: 2020 PMID: 33042359 PMCID: PMC7538121 DOI: 10.1016/j.waojou.2020.100474
Source DB: PubMed Journal: World Allergy Organ J ISSN: 1939-4551 Impact factor: 4.084
International equivalent standards for FFP2- masks
| Name | Country/Region |
|---|---|
| European Union | |
| United States | |
| China | |
| Australia/New Zealand | |
| South Korea | |
| Japan |
Symptoms, nasal endoscopy, and lavage findings in irritative rhinitis patients
| Patient reported nasal symptoms (VAS): | wearing FFP2 | absence of FFP2 | |
|---|---|---|---|
| sneezing VAS (0–10 cm) | 8.04 (1.41) | 4.83 (1.12) | |
| itching VAS (0–10 cm) | 9.16 (1.05) | 3.27 (2.24) | |
| nasal blockage VAS (0–10 cm) | 7.86 (2.31) | 4.72 (3.02) | |
| rhinorrhea VAS (0–10 cm) | 8.13 (2.09) | 2.85 (2.74) | |
| Mucosal edema VAS (0–10 cm) | 6.88 (1.57) | 2.79 (1.06) | |
| irritation VAS (0–10 cm) | 5.74 (1.17) | 5.03 (1.46) | |
| secretion VAS (0–10 cm) | 8.76 (1.94) | 3.22 (1.72) | |
| Tryptase (ng/ml)#, mean (SD) | 41.7 (18.3) | 15.4 (16.9) | |
| ECP (ng/ml)#, mean (SD) | 78.3 (46.7) | 87.1 (50.8) | |
| total IgE (kU/l) | <0.1 | <0.1 | NA |
| number, median (SEM) | 3.8 (7.9) | 0.4 (0.7) | |
| length, median in mm (SEM) | 3.4 (13.7) | 3.1 (11.6) | |
SD, standard deviation; SEM, standard error of the mean; VAS, visual analogue scale.
Higher scores indicate worse status.//#established norm values for nasal tryptase range from 12.0 to 18.7 ng/ml (95% confidence interval) and for ECP from 84.4 to 102.6 ng/ml (16, 19)